Chemical Biology Program

The Gabriela Chiosis Lab

Research

Gabriela Chiosis, PhD

Professor

The goal of my program is to investigate the nature of chronic stress as it occurs in numerous diseases and aging. Our approach takes advantage of the way nature has evolved to control such stresses, and that is by a unique usage of the chaperome, referred to here as the chronic stress chaperome (CSC). The CSC is structurally, dynamically and functionally distinct from the housekeeping chaperome, and my lab has pioneered an approach to take advantage of such feature. By using innovative methods, we develop small molecule chemical tool sets specifically targeted to the CSC; these act as “sensors” of the CSC and, in turn, of the chronic stress-associated proteome. By the use of these unique tool sets we aim to understand, diagnose, and treat cellular processes associated with chronic stress.

View Lab Overview

Research Projects

View All Projects

Chiosis Lab - October 2013

Featured News

In the Lab

Just Add Sugar: How a Protein’s Small Change Leads to Big Trouble for Cells

Tuesday, June 30, 2020

In the Lab

Bull’s-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place

Friday, October 25, 2019

Finding

Study Reveals a New Way That Stress and Aging Lead to Alzheimer’s

Thursday, January 16, 2020

View All Featured News

Publications

The epichaperome is an integrated chaperome network that facilitates tumour survival. Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. Nature. 2016 Oct 5. doi: 10.1038/nature19807.

Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G. Nat Chem Biol. 2013 Sep 1. doi: 10.1038/nchembio.1335. [Epub ahead of print]

Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Rodina A, Patel PD, Kang Y, Patel Y, Baaklini I, Wong MJ, Taldone T, Yan P, Yang C, Maharaj R, Gozman A, Patel MR, Patel HJ, Chirico W, Erdjument-Bromage H, Talele TT, Young JC, Chiosis G. Chem Biol. 2013 Dec 19;20(12):1469-80. doi: 10.1016/j.chembiol.2013.10.008. Epub 2013 Nov 14.

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G. Nat Chem Biol. 2011 Sep 25;7(11):818-26. doi: 10.1038/nchembio.670.

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. doi: 10.1073/pnas.0903392106. Epub 2009 May 5.

View All Publications

People

Gabriela Chiosis, PhD

Professor

The Chiosis lab uses a unique chemical biology approach to understand, diagnose, and treat cellular processes associated with chronic molecular stress, with the ultimate goal of developing novel therapeutic options for use in the clinic.
PhD, Columbia University

chiosisg@mskcc.org: Email Address
646-888-2235: Office Phone

Members

Jenny Matalon

Administrative Assistant

Chander Digwal
Research Fellow - Medicinal Chemist

Piyusha Pagare
Research Scholar - Medicinal Chemist

Lab Alumni

Maria del Carmen Inda Garcia, PhD — Maria del Carmen Inda Garcia
Research Scholar

Chenghua Yang

Research Scholar

Lampros Milanos, PhD — Lampros Milanos
Research Fellow

Mary Alpaugh

Research Associate

Liza Shrestha, PhD — Liza Shrestha
Research Fellow

Raul Alonso

Research Technician

Lab Affiliations

Achievements

AACR – Cancer Research and Prevention Career Development Award in Translational Lung Cancer Research, in Memory of Duffy Wall
Susan G. Komen Breast Cancer Translational Research Award
Frederick R. Adler Chair for Junior Faculty
Award for Drug Discovery Research for Frontotemporal Dementia
Top 5 percent cited author in Biology and Biochemistry 2010 (analysis by Thomson Reuters)

Translated from bench-to-bedside the Hsp90 inhibitor PU-H71 and the non-invasive companion diagnostic 124I-PU-H71 PET assay

Open Positions

Get in Touch

chiosisg@mskcc.org

Lab Head Email
646-888-2235

Office Phone
646-422-0416

Office Fax
646-888-2216/2238

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Gabriela Chiosis discloses the following relationships and financial interests:

Samus Therapeutics LLC
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures